Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy

Figure 4

ROC curves for BAFF, APRIL, and anti-PLA2R serum levels and 24-month clinical outcome. (a) ROC curve analysis to validate the association of BAFF/BLyS serum levels at baseline with the probability to obtain CR/PR after 24-month follow-up (, CI 95% 0.792-0.976, ). (b) ROC curve analysis to validate the association of APRIL serum levels at baseline with the probability to obtain CR/PR after 24-month follow-up (, CI 95% 0.786-0.975, ). (c) ROC curve analysis to validate the association of anti-PLA2R serum levels at baseline with the probability to obtain CR/PR after 24-month follow-up (, CI 95% 0.598-0.875, ).

(a)

(b)

(c)